Complex delivery, simplified.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions.
We consult with and listen to our patients. Our technologies aim to address shortfalls in medication design that make it hard for patients to use the medicines they’re prescribed.
Our therapeutic solutions make life-saving medications available to those who need them most by enhancing the way they are delivered.
We are focused problem solvers who work to empower patients and their caregivers. Our team hails from a variety of backgrounds and disciplines, and has created a collaborative culture where different viewpoints are valued and challenging the status quo is the norm.
We’re fortunate to have experienced industry leaders on our active Board of Directors.
Our advisory board consists of world-renowned, experienced physicians who share our goal of simplifying complex treatment conditions to improve the patient experience in allergy.
